The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of P-glycoprotein (P-gp) substrate (dabigatran) in healthy male participants. This study will last approximately 21 days.

Start Date01 Aug 2026

Sponsor / Collaborator

Deciphera Pharmaceuticals, Inc.

NCT07539090

/ RecruitingPhase 1

A Phase 1, Open-label, Fixed-sequence Study to Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) in Healthy Female Participants

The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.

Start Date05 Jun 2026

Sponsor / Collaborator

Deciphera Pharmaceuticals, Inc.

NCT07158411

/ CompletedPhase 1

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) Inhibition in Healthy Male Participants

The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study will also assess the safety and tolerability when vimseltinib is co-administered with the clinical OCT2 substrate (metformin) in healthy male participants. This study will last approximately 25 days.

Start Date20 Nov 2025

Sponsor / Collaborator

Deciphera Pharmaceuticals, Inc.

100 Clinical Results associated with Vimseltinib

100 Translational Medicine associated with Vimseltinib

100 Patents (Medical) associated with Vimseltinib

Literatures (Medical) associated with Vimseltinib

01 Mar 2026·QUALITY OF LIFE RESEARCH

Mixed-Methods to Define Meaningful Change using Exit Interview and Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT)

Article

Author: Gelderblom, Hans ; Gelhorn, Heather L ; Cutts, Katelyn N ; Zeringo, Nicholas A ; Tap, William ; Harrow, Brooke ; Bernthal, Nicholas ; Van De Sande, Michiel ; Saunders, Amanda ; Tait, Christopher ; Fikre, Tsion ; Han, Yipin

BACKGROUND:

Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm associated with limited range of motion (ROM), stiffness, joint damage, pain, and reduced physical functioning (PF). The MOTION Phase 3 trial (NCT05059262) was a randomized, placebo-controlled, double-blind study of vimseltinib among patients with TGCT. The objective of the current study was to define meaningful changes in clinical outcome assessments (COAs) measuring active ROM, PF, and stiffness using qualitative and quantitative data from patients in the MOTION trial.

METHODS:

Embedded exit interviews with patients in MOTION were conducted to explore meaningful changes in Patient Global Impression of Change (PGIC) anchors, active ROM, Patient-Reported Outcomes Measurement Information System (PROMIS)-PF, and Worst Stiffness numeric rating scale (NRS). Anchor- and distribution-based analyses of the MOTION data, informed by the exit interviews, were used to define responder thresholds.

RESULTS:

In the MOTION trial, 96/123 patients (78%) completed an exit interview. Most considered "minimally improved" responses for each question (PGIC-PF: 67%; PGIC-ROM 73%) as meaningful. Responder estimates ranged from 1.45 to 4.9 (PROMIS-PF), from 6.0 to 14.8 (active ROM), and from - 2.3 to - 0.5 (Stiffness). The cumulative distribution function curves show a clear separation between treatment groups at a wide range of values around the proposed thresholds.

CONCLUSIONS:

The responder definitions were at least a 3-point improvement for PROMIS-PF, a 10% improvement for active ROM, and a 2-point improvement for the Worst Stiffness NRS. Qualitative interviews facilitate integrating the patient perspective in the selection of anchors and defining meaningful change.

02 Jan 2026·EXPERT OPINION ON PHARMACOTHERAPY

Investigating vimseltinib in tenosynovial giant cell tumors

Review

Author: Chugh, Rashmi ; Wytiaz, Victoria

INTRODUCTION:

Tenosynovial giant cell tumors (TGCTs) are locally aggressive mesenchymal neoplasms that can cause chronic disability. Surgery is a mainstay of treatment but can carry a high risk of morbidity or can confer limited benefit. As such, effective alternative treatment options are needed, including systemic agents. Improved understanding of the pathophysiology of TGCTs has led to such drug development.

AREAS COVERED:

Vimseltinib is a switch-control tyrosine kinase inhibitor designed to selectively inhibit CSF1R, which, along with CSF1, is responsible for the synovial inflammation that characterizes TGCTs. In this drug evaluation, we review the mechanism of action, pharmacologic properties, clinical efficacy and current role within the TGCT treatment landscape of vimseltinib.

EXPERT OPINION:

Vimseltinib demonstrated a significant response rate as well as meaningful symptomatic improvement in patients with TGCTs. Furthermore, there is an absence of severe toxicities that have arisen with other agents in the TGCT treatment space, specifically liver failure. Vimseltinib is a favorable option for patients with TGCTs and further efforts to determine its place in the sequence of overall management are needed.

01 Aug 2025·ESMO Open

A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma

Article

Author: Wong, P ; Antonescu, C R ; D'Angelo, S P ; Biniakewitz, M ; Chan, J E ; Gounder, M M ; Hwang, S ; Movva, S ; Qin, L-X ; Rosenbaum, E ; Avutu, V ; Desir, R ; Chi, P ; Keohan, M L ; Tap, W D ; Nacev, B A ; Dickson, M A ; Seier, K ; Jasnani, S ; Kelly, C M ; Bradic, M ; Erinjeri, J ; Duchemin, M

BACKGROUND:

Sarcomas are frequently infiltrated with immunosuppressive myeloid cells. Vimseltinib is an inhibitor of the colony-stimulating factor 1 receptor kinase and has been shown to decrease tumor-infiltrating myeloid cells in preclinical models. We hypothesized that vimseltinib combined with the Programmed death-ligand 1 (PD-L1) inhibitor avelumab would be safe, tolerable, and clinically effective in patients with advanced sarcoma.

METHODS:

This was a phase I study of vimseltinib plus avelumab in patients with unresectable or metastatic sarcoma. The study used a standard 3 + 3 dose-escalation design, followed by dose expansion in patients with select histological subtypes. Vimseltinib was administered daily by mouth in 28-day cycles; avelumab was administered intravenously every 2 weeks. The primary objectives of the dose-escalation and dose-expansion phases were to determine the recommended phase II dose and to estimate the best objective response rate by RECIST version 1.1.

RESULTS:

Thirteen patients were treated in the dose-escalation phase, and 19 patients were treated in the dose-expansion phase. The most common treatment-related adverse events were asymptomatic increases in serum levels of amylase, lipase, creatine phosphokinase, aspartate aminotransferase, and alanine aminotransferase. One of six patients treated at the highest dose level had a dose-limiting toxicity (grade 4 increase in aspartate aminotransferase). The highest dose level was determined to be the recommended phase II dose. There were no objective responses. The median progression-free survival of patients treated at the recommended phase II dose was 1.55 months (95% confidence interval 1.25-1.78 months). Flow cytometric analysis of peripheral blood mononuclear cells revealed a decrease in myeloid-derived suppressor cells and regulatory T cells after treatment. RNA sequencing of paired tumor samples revealed an increase in tumor-infiltrating T cells and a decrease in macrophages after treatment.

CONCLUSIONS:

Vimseltinib plus avelumab was generally safe and well tolerated. This combination had minimal clinical efficacy in our population of heavily pretreated patients with sarcoma.

News (Medical) associated with Vimseltinib

17 Jun 2026

·www.businesswire.com

Deciphera Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 INTREPID Study of Sapablursen in Polycythemia Vera

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), announced the first patient was dosed in the global pivotal Phase 3 INTREPID study evaluating sapablursen for the treatment of polycythemia vera (PV). Sapablursen is an investigational drug that has the potential to offer a once-monthly treatment option for patients with PV, a rare and potentially life-threatening hematologic disease. “We look forward to building upon the positive efficacy and safety results from the Phase 2a IMPRSSION study, which demonstrated the ability of sapablursen to reduce the frequency of phlebotomy, control hematocrit, and improve PV symptoms in patients treated with phlebotomy alone and those on cytoreductive therapies,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “Sapablursen has the potential to be an important new treatment option for patients with PV, and we are excited to begin our Phase 3 INTREPID study, which brings us one step closer to addressing the unmet needs of these patients.” INTREPID is a pivotal global Phase 3 study in patients with phlebotomy-dependent PV designed to compare the efficacy and safety of sapablursen to placebo over a 32-week double-blind treatment period followed by up to 124 weeks of open label treatment. The primary endpoint is response, defined by the absence of phlebotomy eligibility. Key secondary endpoints are number of phlebotomies, which is the primary endpoint for the European Medicines Agency for potential regulatory approval, hematocrit control, and improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form Total T-score and the Myelofibrosis Symptom Assessment Form (MFSAF) Total Symptom Score. Durability of response will be evaluated in patients randomized to sapablursen over 52 weeks of study treatment, including 32 weeks of blinded treatment and 20 weeks of open-label treatment. The INTREPID clinical trial has initiated in the United States and is planned in additional regions including North America, Latin America, Asia Pacific and Europe. For more information on the INTREPID study, please visit https://clinicaltrials.gov/study/NCT07429266. Sapablursen received Fast Track designation and Orphan Drug Designation in 2024 and Breakthrough Therapy Designation in 2025 by the U.S. Food and Drug Administration (FDA). Sapablursen was discovered and advanced through Phase 2 clinical development by Ionis Pharmaceuticals. Ono obtained exclusive global rights for the development and commercialization of sapablursen after entering into a license agreement with Ionis in March 2025. About Sapablursen Sapablursen is designed to reduce the production of TMPRSS6 resulting in increased expression of hepcidin, the key regulator of iron homeostasis. By increasing the production of hepcidin, sapablursen has the potential to positively impact PV by decreasing hematocrit, reducing the need for phlebotomy, and improving quality of life. About Polycythemia Vera Polycythemia vera (PV) is a rare and potentially life-threatening hematologic disease characterized by the overproduction of red blood cells, which significantly increases the risk of serious blood clots, heart attack, stroke, and death. The primary treatment goal in PV is to maintain blood hematocrit levels <45% to prevent thrombotic events and alleviate burdensome symptoms, such as severe fatigue, difficulty concentrating, night sweats, and pruritus. Current treatment options often worsen symptoms and inadequately maintain hematocrit control. About Deciphera Pharmaceuticals, LLC Deciphera, a member of Ono Pharmaceutical Co., Ltd., is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines and providing hope to people living with cancer, neurologic, and autoimmune disease. Deciphera is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from Deciphera’s platform in clinical studies, QINLOCK® (ripretinib) is Deciphera’s switch-control kinase inhibitor approved in many countries including the European Union and the United States for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ROMVIMZATM (vimseltinib) is a kinase inhibitor approved in the United States for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity, and in the European Union for adult patients with TGCT associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera). About Ono Pharmaceutical Co., Ltd. Ono Pharmaceutical Co., Ltd. delivers innovative medicines for patients worldwide. Upholding its philosophy of “Dedicated to the Fight against Disease and Pain,” Ono targets areas with unmet medical needs including oncology, immunology & inflammation, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en. Cautionary Note Regarding Forward-Looking Statements In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice.

Phase 3Orphan DrugClinical ResultPhase 2Fast Track

13 Apr 2026

·www.fiercebiotech.com

BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types

BioNTech and SynOx plan to file for FDA approvals this year.\n The fight for two tumor types is poised to intensify, with BioNTech lining up a challenge to AstraZeneca, while SynOx Therapeutics is planning to enter a market served by companies including Daiichi Sankyo.BioNTech’s data come from a phase 2 trial of its Duality Biologics-partnered antibody-drug conjugate (ADC) trastuzumab pamirtecan. The biotech reported a 49.3% response rate to the HER2-targeted ADC in a phase 2 cohort of 73 patients with HER2-expressing, advanced endometrial cancer who progressed on or after first-line chemotherapy and checkpoint inhibitor therapy, hitting its primary endpoint.The primary analysis cohort was part of a broader study that included people without prior exposure to checkpoint inhibitor therapy. Across all 96 centrally tested patients, BioNTech reported a response rate of 47.9% and median progression-free survival of 8.1 months. The response rate fell to 44.1% in the full, 143-patient cohort, which included patients tested for HER2 at their trial site or local laboratory. BioNTech said the safety profile was manageable and as expected for HER2-targeted ADCs. Almost 47% of patients had grade 3 or greater treatment-related adverse events. Almost 5% of patients had grade 3 or greater interstitial lung disease (ILD) or pneumonitis. AstraZeneca and Daiichi’s HER2-directed ADC Enhertu carries a boxed warning for ILD and pneumonitis. The FDA approved Enhertu in adults with unresectable or metastatic HER2-positive solid tumors in 2024. The tumor-agnostic authorization was supported (PDF) by data including a 56.3% response rate in 16 endometrial cancer patients. BioNTech, which hailed its trial as the largest in the indication, plans to file for FDA approval this year.Separately, SynOx aims to file for FDA approval of emactuzumab in tenosynovial giant cell tumor (TGCT) patients in the second half of the year. SynOx outlined the plan as part of the release of phase 3 data on the CSF1R inhibitor, which achieved a significantly better response rate than placebo at Month 6 to hit the primary endpoint. The biotech also reported hits on secondary endpoints.Daiichi won FDA approval for a CSF1R inhibitor, Turalio, in TGCT in 2019. Last year, Ono Pharmaceutical got the green light to sell a rival drug, Romvimza, that it acquired in its $2.4 billion takeover of Deciphera. Merck KGaA filed for FDA approval of another CSF1R inhibitor, pimicotinib, in the indication in January. Having ceded a head start to rivals, SynOx is positioning the former Roche antibody emactuzumab as a differentiated, short-course treatment. Phase 3 participants received emactuzumab intravenously every two weeks for eight weeks. Turalio (PDF) and Romvimza (PDF) are given orally, respectively twice daily and twice weekly. Merck tested once-daily pimicotinib in its phase 3 trial.

Clinical ResultDrug ApprovalPhase 3ADCPhase 2

13 Apr 2026

·allsci.com

SynOx’s CSF-1R antibody emactuzumab set for approval filing in TCGT after strong Phase III

SynOx Therapeutics reported that CSF-1R-targeted antibody emactuzumab met both primary and secondary endpoints in the Phase III TANGENT study in tenosynovial giant cell tumor (TCGT), with statistically significant improvements in tumor response and patient-reported functional outcomes versus placebo. SynOx indicated that the data will support a Biologics License Application submission to the FDA in the second half of 2026. The TANGENT trial (NCT05417789) is a global, randomized, double-blind, placebo-controlled Phase III study enrolling adults with biopsy-confirmed localized or diffuse TGCT for whom surgery would worsen functional outcomes or carry high recurrence risk. Emactuzumab, dosed at 1,000 mg intravenously every two weeks for five doses over eight weeks, produced statistically significant improvements in objective response rate by RECIST v1.1 — the primary endpoint — at six months. Key secondary endpoints, including Tumor Volume Score, PROMIS-PF physical function T-score, range of motion, pain, and stiffness, also met significance thresholds. The company did not disclose specific response rate figures in the topline release, with full data expected at an upcoming medical meeting. The safety profile was consistent with prior clinical experience, with no new signals identified. The target rationale The mechanistic rationale for emactuzumab in TGCT is well-established. TGCT is driven by pathological overexpression of CSF1, the primary ligand for CSF-1R, which recruits and sustains the macrophage-rich tumor microenvironment that defines the disease. Emactuzumab is a high-affinity anti-CSF-1R monoclonal antibody that blocks receptor activation and depletes tumor-promoting macrophages — the same pathway targeted by the two approved oral agents in this space, pexidartinib (Turalio) and vimseltinib (Romvimza). Pexidartinib, a multi-kinase small-molecule inhibitor, received FDA approval in 2019 on the basis of the ENLIVEN trial, which showed a 38% objective response rate versus 0% with placebo. Its label carries a boxed warning for serious and potentially fatal hepatotoxicity and requires a REMS program. Vimseltinib, a more selective switch-control CSF-1R kinase inhibitor with twice-weekly oral dosing, gained approval in February 2025 following positive Phase III MOTION data, posting a 46% response rate versus 4% with placebo, without the hepatotoxicity profile that constrained pexidartinib’s uptake. Both approved agents require continuous, indefinite administration. That is the structural feature emactuzumab is designed to disrupt. SynOx is positioning the antibody as a short-course induction therapy — eight weeks of treatment intended to produce durable disease control without ongoing dosing. The TANGENT data, as described in the topline release, show that functional benefits were observed rapidly and persisted beyond the treatment window, though the durability follow-up period extends to 18 months and full characterization is ongoing. The clinical logic for a finite-course approach is grounded in the disease context. TGCT is non-malignant but locally aggressive, primarily affecting patients between ages 35 and 50 — a population expected to live with the disease, and its treatment, for decades. Chronic oral TKI therapy in this setting carries cumulative tolerability risk and daily adherence burden that are not trivial considerations when the underlying condition is not life-threatening. The TANGENT protocol also allows retreatment with open-label emactuzumab for patients who progress during the follow-up phase, preserving a rescue option without committing patients to indefinite systemic therapy from the outset. The TANGENT response rate — once disclosed in full — cannot be directly benchmarked against the ENLIVEN or MOTION figures. What can be assessed structurally is the modality distinction: emactuzumab’s antibody format offers receptor-level blockade rather than intracellular kinase inhibition, a mechanistic difference that may carry different resistance and tolerability implications, though no comparative data exist. The TGCT market is small by oncology standards — an estimated 200,000 patients in the US and 179,000 in the EU plus UK, with an incidence of approximately 50 per million — but the disease’s chronicity and the working-age demographic create a commercially relevant patient population with long treatment horizons. SynOx is privately held and backed by Forbion, Gilde Healthcare, HealthCap, Bioqube Ventures, and Medicxi. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Clinical ResultPhase 3Drug ApprovalImmunotherapy

100 Deals associated with Vimseltinib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Giant Cell Tumor of Tendon Sheath	United States	Deciphera Pharmaceuticals, Inc.	14 Feb 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic graft-versus-host disease	Phase 2	United States	Deciphera Pharmaceuticals, Inc.	21 Nov 2024
Advanced cancer	Phase 2	United States	Deciphera Pharmaceuticals, Inc.	16 Feb 2017
Advanced cancer	Phase 2	Australia	Deciphera Pharmaceuticals, Inc.	16 Feb 2017
Advanced cancer	Phase 2	Canada	Deciphera Pharmaceuticals, Inc.	16 Feb 2017
Advanced cancer	Phase 2	France	Deciphera Pharmaceuticals, Inc.	16 Feb 2017
Advanced cancer	Phase 2	Italy	Deciphera Pharmaceuticals, Inc.	16 Feb 2017
Advanced cancer	Phase 2	Netherlands	Deciphera Pharmaceuticals, Inc.	16 Feb 2017
Advanced cancer	Phase 2	Poland	Deciphera Pharmaceuticals, Inc.	16 Feb 2017
Advanced cancer	Phase 2	Spain	Deciphera Pharmaceuticals, Inc.	16 Feb 2017
Advanced cancer	Phase 2	United Kingdom	Deciphera Pharmaceuticals, Inc.	16 Feb 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06619561 (Tandem Meetings ASTCT and CIBMTR2026)	Phase 2	Chronic graft-versus-host disease	15	Vimseltinib	tbjucdgiwm(ldgjrensnw) = cvvcuaflde xdhpkkuqxu (qokkzskmpb )	Positive	04 Feb 2026
NCT05059262 (MOTION, ESMO2025)	Phase 3	Giant Cell Tumor of Tendon Sheath	83	Vimseltinib 30 mg	imysmrdaem(grnliuvanh) = oivlramijj inswoqaemy (aaxbfyhkak, 37 - 59) View more	Positive	17 Oct 2025
NCT05059262 (MOTION, ASCO2025)	Phase 3	Giant Cell Tumor of Tendon Sheath CSF1	83	Vimseltinib 30 mg twice weekly	nacojcpcrj(ekvotprhqx) = nojmkutkdy lljwfgpagf (qeitcfjrze, 29 - 51) View more	Positive	30 May 2025
NCT05059262 (MOTION, CTgov)	Phase 3	Giant Cell Tumor of Tendon Sheath	123	Vimseltinib (Vimseltinib)	ikvsdilaeg = daenubukyk lcwktbmmzs (iywrlnlxrm, vkvemcgvuo - hsjrdgsuxn) View more	-	24 Feb 2025
				placebo (Placebo)	ikvsdilaeg = ilhccvfamg lcwktbmmzs (iywrlnlxrm, hjtbslpmit - nnhgehqafi) View more
NCT03069469 (ESMO2024)	Phase 1/2	Giant Cell Tumor of Tendon Sheath	-	Vimseltinib 30 mg	pnyngkngzp(equxxiwivo) = Grade 3/4 TEAEs (>5% of pts) were increased creatine phosphokinase, hypertension, and eczema. aodfrbsvtl (yeadvaqgwd ) View more	-	14 Sep 2024
				Placebo
NCT03069469 (ESMO2024)	Phase 1/2	Giant Cell Tumor of Tendon Sheath	-	Vimseltinib 30 mg	ikzkugzywi(nazhqfodrq) = sapfxdpcik qxidosflmh (xejkkzjrvb ) View more	-	14 Sep 2024
NCT05059262 (MOTION, Pubmed \| Lancet)	Phase 3	Giant Cell Tumor of Tendon Sheath	123	Vimseltinib 30 mg	srtqqpvzxb(endpikzrpk) = pftdsxaaln euzwddlqwb (letyzrtlru, 29 - 51)	Positive	01 Jun 2024
NCT05059262 (MOTION, ASCO2024) Manual	Phase 3	Giant Cell Tumor of Tendon Sheath	123	Vimseltinib 30 mg	haxhofzstc(sffyupekdj) = jslirjmqrp riwaytvyxj (whrsubwpqp ) View more	Positive	24 May 2024
				Placebo	haxhofzstc(sffyupekdj) = iayzyobfjv riwaytvyxj (whrsubwpqp ) View more
NCT05059262 (MOTION, Biospace \| FDA) Manual	Phase 3	Giant Cell Tumor of Tendon Sheath	123	vimseltinib	xkdrnfiqfm(tywzpcbtul) = hikogocwyt frrnthiohz (lkuoillxbc, 29 - 51) Met View more	Positive	30 Oct 2023
				Placebo	xkdrnfiqfm(tywzpcbtul) = lffztllcqi frrnthiohz (lkuoillxbc, 0 - 9) Met View more
NCT03069469 (Biospace) Manual	Phase 1/2	Giant Cell Tumor of Tendon Sheath CSF1R	97	vimseltinib (Phase 1)	bdnzmspgoi(hcvxxgjpkk) = rzeoyupqji qyfdkfkoaq (flmshjqrkn ) View more	Positive	30 Oct 2023
				vimseltinib (Phase 2 Cohort A)	bdnzmspgoi(hcvxxgjpkk) = oyhymdmvpc qyfdkfkoaq (flmshjqrkn ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis